Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pureos Bioventures is a venture capital firm founded in Switzerland, focusing on investments in private companies that are pioneering innovative drug development. Established to advance next-generation biological drugs and drug formats, the firm targets severe diseases, including cancer, fibrotic diseases, and neurological disorders. Pureos Bioventures operates as Pureos Partners AG, with its general partner entity registered in Bermuda as BB Pureos Bioventures GP Ltd.
The firm manages a fund size of $205 million, which was expanded from an initial close of $170 million in 2020. Pureos Bioventures has a total of 33 investments across its portfolio, primarily in Europe, with a strong concentration in Switzerland. The firm is recognized as the largest institutional Swiss venture capital firm dedicated solely to private biotech investments.
Pureos Bioventures has established itself as a key player in the biotech sector, actively engaging with its portfolio companies and providing operational support to accelerate clinical development. The firm is also involved with BaseLaunch, an incubator and accelerator for biotech companies in Switzerland, further solidifying its commitment to fostering innovation in the biopharmaceutical space.
Pureos Bioventures specializes in investing in companies that develop innovative therapeutics within the biopharmaceutical sector. The firm focuses on clinical-stage and preclinical companies that are working on groundbreaking treatments for severe diseases, particularly in oncology, fibrotic diseases, and neurological disorders. Their investment strategy emphasizes next-generation biological drugs and drug formats, including protein-based therapeutics and antibody-drug conjugates.
The firm typically invests at the pre-seed, seed, and Series A stages, often co-leading investment rounds to ensure that portfolio companies receive both financial backing and strategic guidance. Pureos Bioventures seeks to partner with founders who are dedicated to advancing novel therapeutics and are positioned to make a significant impact in their respective fields. The firm maintains a Europe-first geographic focus, with a strong emphasis on Swiss companies, while remaining opportunistic in global investments.
Pureos Bioventures has a diverse portfolio of 33 companies, primarily in the biotech and healthcare sectors. Notable portfolio companies include:
Pureos Bioventures has achieved notable exits, including the acquisition of Araris Biotech and ImCheck Therapeutics, as well as the IPO of LAVA Therapeutics.
Dr. Dominik Escher - Managing Partner: Dr. Escher is a founding partner of Pureos Bioventures and has a strong background in the biotech industry. He was the founder and CEO of ESBATech, which was acquired by Alcon/Novartis in 2009 for $589 million. He is also the co-founder and Executive Chairman of CDR-Life, showcasing his extensive experience in drug development and commercialization.
Klaus Breiner - Partner: Klaus brings significant expertise in the biotech sector, contributing to the firm's investment strategy and portfolio management.
Anja Harmeier - Partner: Anja is involved in sourcing and evaluating investment opportunities, leveraging her background in biopharmaceuticals.
Martin Munchbach - Partner: Martin focuses on operational support and strategic guidance for portfolio companies, enhancing their clinical development efforts.
To pitch Pureos Bioventures, founders should utilize the contact form available on their website at pureosbio.com. It is important to include a comprehensive pitch deck that outlines the startup's mission, the therapeutic area of focus, the stage of development, and the qualifications of the founding team. Founders should also highlight any clinical data or partnerships that support their business case.
While specific response time expectations are not publicly disclosed, founders can expect a thorough review process. A warm introduction through mutual connections in the biotech industry may enhance the chances of receiving a timely response.
In March 2025, Pureos Bioventures achieved a significant milestone with the acquisition of Araris Biotech by Taiho Pharmaceutical for up to $1.14 billion, marking a major exit for the firm. This acquisition is expected to generate a strong DPI (Distributions to Paid-In) for the firm and accelerate the closing of Fund II.
Additionally, Pureos Bioventures has been actively sharing updates about their portfolio companies through blog posts, covering topics such as licensing agreements, clinical trial advancements, and financing rounds. This ongoing engagement highlights the firm's commitment to supporting its portfolio companies in the biotech sector.
What are Pureos Bioventures' investment criteria?
Pureos Bioventures invests in private companies focused on innovative drug development, particularly in the biopharmaceutical sector. They prioritize clinical-stage and preclinical companies developing novel therapeutics for severe diseases, including cancer and fibrotic conditions.
How can founders pitch to Pureos Bioventures?
Founders can pitch their companies through the Pureos Bioventures website at pureosbio.com. It is advisable to include detailed information about the therapeutic area, stage of development, and the team’s expertise in the pitch deck.
What makes Pureos Bioventures different from other VCs?
Pureos Bioventures is distinguished by its exclusive focus on the biopharmaceutical sector, particularly next-generation biological drugs. The firm provides operational support to its portfolio companies, leveraging the clinical operations expertise of its general partner team.
What is the geographic scope of Pureos Bioventures?
The firm primarily focuses on investments in Europe, with a strong concentration in Switzerland. However, they are open to opportunistic investments globally.
What is the typical check size for investments?
While specific check sizes are not disclosed, Pureos Bioventures typically invests at the pre-seed, seed, and Series A stages, often co-leading rounds to provide substantial financial backing.
What kind of post-investment involvement does Pureos Bioventures have?
Pureos Bioventures actively engages with its portfolio companies, providing operational support and strategic guidance to accelerate clinical development and enhance growth opportunities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.